Blueprint Medicines’ (BPMC) Outperform Rating Reiterated at Wedbush
Wedbush reaffirmed their outperform rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a research report report published on Monday morning, Marketbeat.com reports. They currently have a $124.00 price target on the biotechnology company’s stock, down from their prior price target of $135.00. Several other research firms have also recently weighed in on […]
More Stories
Mereo BioPharma Group’s (MREO) “Buy” Rating Reiterated at Needham & Company LLC
Needham & Company LLC restated their buy rating on shares of Mereo BioPharma Group (NASDAQ:MREO – Free Report) in a...
Rockingstone Advisors LLC Makes New Investment in Natera, Inc. (NASDAQ:NTRA)
Rockingstone Advisors LLC bought a new position in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) during the fourth quarter,...
Humacyte’s (HUMA) Buy Rating Reiterated at D. Boral Capital
D. Boral Capital restated their buy rating on shares of Humacyte (NASDAQ:HUMA – Free Report) in a research note released...
Rockingstone Advisors LLC Buys New Stake in iShares Core S&P Small-Cap ETF (NYSEARCA:IJR)
Rockingstone Advisors LLC purchased a new position in shares of iShares Core S&P Small-Cap ETF (NYSEARCA:IJR – Free Report) in...
Fifth Third Wealth Advisors LLC Acquires 1,553 Shares of 3M (NYSE:MMM)
Fifth Third Wealth Advisors LLC lifted its holdings in shares of 3M (NYSE:MMM – Free Report) by 21.5% in the...
Allen Mooney & Barnes Investment Advisors LLC Cuts Stock Position in Costco Wholesale Co. (NASDAQ:COST)
Allen Mooney & Barnes Investment Advisors LLC decreased its holdings in shares of Costco Wholesale Co. (NASDAQ:COST – Free Report)...